-
Three-dimensional chromatin analysis reveals Sp1 as a mediator to program and reprogram HPV-host epigenetic architecture in cervical cancer Cancer Lett. (IF 9.7) Pub Date : 2024-03-11 Canhui Cao, Qian Xu, Zhixian Zhu, Miaochun Xu, Ye Wei, Shitong Lin, Sheng Cheng, Wenhua Zhi, Ping Hong, Xingyu Huang, Da Lin, Gang Cao, Yifan Meng, Ping Wu, Ting Peng, Juncheng Wei, Wencheng Ding, Xiaoyuan Huang, WingKin Sung, Gang Chen, Ding Ma, Guoliang Li, Peng Wu
Human papillomavirus (HPV) is predominantly associated with HPV-related cancers, however, the precise mechanisms underlying the HPV-host epigenetic architectures in HPV carcinogenesis remain elusive. Here, we employed high-throughput chromosome conformation capture (Hi-C) to comprehensively map HPV16/18-host chromatin interactions. Our study identified the transcription factor Sp1 as a pivotal mediator
-
Lactate enhances NMNAT1 lactylation to sustain nuclear NAD+ salvage pathway and promote survival of pancreatic adenocarcinoma cells under glucose-deprived conditions Cancer Lett. (IF 9.7) Pub Date : 2024-03-11 Huimin Huang, Shitong Wang, Hongping Xia, Xingling Zhao, Kaiyuan Chen, Guihua Jin, Shipeng Zhou, Zhaoliang Lu, Tongke Chen, Huajun Yu, Xiaoqun Zheng, Haishan Huang, Linhua Lan
The aim of this study was to investigate the underlying molecular mechanism behind the promotion of cell survival under conditions of glucose deprivation by -lactate. To accomplish this, we performed tissue microarray and immunohistochemistry staining to analyze the correlation between the abundance of pan-Lysine lactylation and prognosis. evaluations of tumor growth were conducted using the KPC and
-
Targeting PARP14 with lomitapide suppresses drug resistance through the activation of DRP1-induced mitophagy in multiple myeloma Cancer Lett. (IF 9.7) Pub Date : 2024-03-11 Honghao Zhang, Hao Wang, Yuxing Hu, Yang Gao, Jianyu Chen, Yabo Meng, Yingqi Qiu, Rong Hu, Peiyun Liao, Meifang Li, Yanjie He, Zhao Liang, Xiaoling Xie, Yuhua Li
Multiple myeloma (MM) is a hematological malignancy that remains incurable, primarily due to the high likelihood of relapse or development of resistance to current treatments. To explore and discover new medications capable of overcoming drug resistance in MM, we conducted cell viability inhibition screens of 1504 FDA-approved drugs. Lomitapide, a cholesterol-lowering agent, was found to exhibit effective
-
Hypoxia-induced TREM1 promotes mesenchymal-like states of glioma stem cells via alternatively activating tumor-associated macrophages Cancer Lett. (IF 9.7) Pub Date : 2024-03-11 Minhai Dong, Xiaolin Zhang, Peng Peng, Zirong Chen, Yang Zhang, Lijun Wan, Wang Xiang, Guohao Liu, Yang Guo, Qungen Xiao, Baofeng Wang, Dongsheng Guo, Min Zhu, Xingjiang Yu, Feng Wan
The mesenchymal subtype of glioblastoma (GBM) cells characterized by aggressive invasion and therapeutic resistance is thought to be dependent on cell-intrinsic alteration and extrinsic cellular crosstalk. Tumor-associated macrophages (TAMs) are pivotal in tumor progression, chemo-resistance, angiogenesis, and stemness maintenance. However, the impact of TAMs on the shifts in glioma stem cells (GSCs)
-
Characterization of the distinct immune microenvironments between hepatocellular carcinoma and intrahepatic cholangiocarcinoma Cancer Lett. (IF 9.7) Pub Date : 2024-03-11 Siao Jiang, Hao Lu, Yingwei Pan, Aiqing Yang, Ainiwaer Aikemu, Hao Li, Rongjiao Hao, Qilin Huang, Xin Qi, Zongjian Tao, Yinglong Wu, Cheng Quan, Gangqiao Zhou, Yiming Lu
As two major types of primary liver cancers, the tumor immune microenvironment (TIME) of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) have been well studied separately. However, a systemic assessment of the similarities and differences between the TIME of HCC and ICC is still lacking. In this study, we pictured a landscape of combined TIME of HCC and ICC by sequencing and
-
Intratumoral injection of interferon gamma promotes the efficacy anti-PD1 treatment in colorectal cancer Cancer Lett. (IF 9.7) Pub Date : 2024-03-11 Yang Tang, Jingsun Wei, Xiaoxu Ge, Chengxuan Yu, Wei Lu, Yucheng Qian, Hang Yang, Dongliang Fu, Yimin Fang, Yinyi Zhou, Zhanhuai Wang, Qian Xiao, Kengfeng Ding
Immune checkpoint inhibitors (ICIs) offer new options for the treatment of patients with solid cancers worldwide. The majority of colorectal cancers (CRC) are proficient in mismatch-repair (pMMR) genes, harbors few tumor antigens and is insensitive to ICIs. These tumors are often found to be immune-deserted. We hypothesized that forcing immune cell infiltration into the tumor microenvironment followed
-
PCTA, a pan-cancer cell line transcriptome atlas Cancer Lett. (IF 9.7) Pub Date : 2024-03-09 Siyuan Cheng, Lin Li, Xiuping Yu
A substantial volume of RNA sequencing data were generated from cancer cell lines. However, it requires specific bioinformatics skills to compare gene expression levels across cell lines. This has hindered non-bioinformaticians from fully utilizing these valuable datasets in their research. To bridge this gap, we established a curated Pan-cancer Cell Line Transcriptome Atlas (PCTA) dataset. This resource
-
Myotubularin-related-protein-7 inhibits mutant (G12V) K-RAS by direct interaction Cancer Lett. (IF 9.7) Pub Date : 2024-03-09 Philip Weidner, Daniel Saar, Michaela Söhn, Torsten Schroeder, Yanxiong Yu, Frank G. Zöllner, Norbert Ponelies, Xiaobo Zhou, André Zwicky, Florian N. Rohrbacher, Vijaya R. Pattabiraman, Matthias Tanriver, Alexander Bauer, Hazem Ahmed, Simon M. Ametamey, Philipp Riffel, Rony Seger, Jeffrey W. Bode, Rebecca C. Wade, Matthias P.A. Ebert, Birthe B. Kragelund, Elke Burgermeister
Inhibition of K-RAS effectors like B-RAF or MEK1/2 is accompanied by treatment resistance in cancer patients via re-activation of PI3K and Wnt signaling. We hypothesised that myotubularin-related-protein-7 (MTMR7), which inhibits PI3K and ERK1/2 signaling downstream of RAS, directly targets RAS and thereby prevents resistance. Using cell and structural biology combined with animal studies, we show
-
LRP1 induces anti-PD-1 resistance by modulating the DLL4-NOTCH2-CCL2 axis and redirecting M2-like macrophage polarisation in bladder cancer Cancer Lett. (IF 9.7) Pub Date : 2024-03-08 Hansen Lin, Liangmin Fu, Xinwei Zhou, Anze Yu, Yuhang Chen, Wuyuan Liao, Guannan Shu, Lizhen Zhang, Lei Tan, Hui Liang, Zhu Wang, Qiong Deng, Jieyan Wang, Meiyu Jin, Zhenhua Chen, Jinhuan Wei, Jiazheng Cao, Wei Chen, Xiaofei Li, Pengju Li, Jun Lu, Junhang Luo
The tumour microenvironment (TME) drives bladder cancer (BLCA) progression. Targeting the TME has emerged as a promising strategy for BLCA treatment in recent years. Furthermore, checkpoint blockade therapies are only beneficial for a minority of patients with BLCA, and drug resistance is a barrier to achieving significant clinical effects of anti-programmed cell death protein-1 (PD-1)/programmed death
-
The mast cell-T lymphocyte axis impacts cancer: Friend or foe? Cancer Lett. (IF 9.7) Pub Date : 2024-03-08 Vinicius Kannen, Denis M. Grant, Jason Matthews
Crosstalk between mast cells (MCs) and T lymphocytes (TLs) releases specific signals that create an environment conducive to tumor development. Conversely, they can protect against cancer by targeting tumor cells for destruction. Although their role in immunity and cancer is complex, their potential in anticancer strategies is often underestimated. When peripheral MCs are activated, they can affect
-
Induction of IFIT1/IFIT3 and inhibition of Bcl-2 orchestrate the treatment of myeloma and leukemia via pyroptosis Cancer Lett. (IF 9.7) Pub Date : 2024-03-08 Yuanming He, Shuoyi Jiang, Yaoli Cui, Jingpei Liang, Yueya Zhong, Yuening Sun, Michael F. Moran, Zhenqian Huang, Guisong He, Xinliang Mao
Induction of pyroptosis is proposed as a promising strategy for the treatment of hematological malignancies, but little is known. In the present study, we find clioquinol (CLQ), an anti-parasitic drug, induces striking myeloma and leukemia cell pyroptosis on a drug screen. RNA sequencing reveals that the interferon-inducible genes IFIT1 and IFIT3 are markedly upregulated and are essential for CLQ-induced
-
Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer Cancer Lett. (IF 9.7) Pub Date : 2024-03-08 Parham Jabbarzadeh Kaboli, Hsiao-Fan Chen, Ali Babaeizad, Kiarash Roustai Geraylow, Hirohito Yamaguchi, Mien-Chie Hung
Breast cancer is the most common malignancy among women, posing a formidable health challenge worldwide. In this complex landscape, the c-MET (cellular-mesenchymal epithelial transition factor) receptor tyrosine kinase (RTK), also recognized as the hepatocyte growth factor (HGF) receptor (HGFR), emerges as a prominent protagonist, displaying overexpression in nearly 50% of breast cancer cases. Activation
-
A unique circulating microRNA pairs signature serves as a superior tool for early diagnosis of pan-cancer Cancer Lett. (IF 9.7) Pub Date : 2024-03-07 Peng Wu, Dongyu Li, Chaoqi Zhang, Bing Dai, Xiaoya Tang, Jingjing Liu, Yue Wu, Xingwu Wang, Ao Shen, Jiapeng Zhao, Xiaohui Zi, Ruirui Li, Nan Sun, Jie He
Cancer remains a major burden globally and the critical role of early diagnosis is self-evident. Although various miRNA-based signatures have been developed in past decades, clinical utilization is limited due to a lack of precise cutoff value. Here, we innovatively developed a signature based on pairwise expression of miRNAs (miRPs) for pan-cancer diagnosis using machine learning approach. We analyzed
-
Potential therapeutic strategy for cancer: Multi-dimensional cross-talk between circRNAs and parental genes Cancer Lett. (IF 9.7) Pub Date : 2024-03-06 Xiaoyu Sun, Xinyi Zhao, Yan Xu, Yuanyuan Yan, Li Han, Minjie Wei, Miao He
In many ways, circular RNAs (circRNAs) have been demonstrated to be crucial in the onset and advancement of cancer throughout the last ten years and have become a new focus of intense research in the field of RNAs. Accumulating studies have demonstrated that circRNAs can regulate parental gene expression a variety of biological pathways. Furthermore, research into the complex interactions between circRNAs
-
Association of preoperative aspartate aminotransferase to platelet ratio index with outcomes and tumour microenvironment among colorectal cancer with liver metastases Cancer Lett. (IF 9.7) Pub Date : 2024-03-06 Qichen Chen, Yiqiao Deng, Yuan Li, Jinghua Chen, Rui Zhang, Lang Yang, Rui Guo, Baocai Xing, Peirong Ding, Jianqiang Cai, Hong Zhao
This study aims to investigate applicable robust biomarkers that can improve prognostic predictions for colorectal liver metastasis (CRLM) patients receiving simultaneous resection. A total of 1323 CRLM patients from multiple centres were included. The preoperative aspartate aminotransferase to platelet ratio index (APRI) level from blood of patients were obtained. Patients were stratified into a high
-
Molecular mechanisms in regulation of autophagy and apoptosis in view of epigenetic regulation of genes and involvement of liquid-liquid phase separation Cancer Lett. (IF 9.7) Pub Date : 2024-03-06 Subhajit Chakraborty, Piyasa Nandi, Jagdish Mishra, Niharika, Ankan Roy, Soumen Manna, Tirthankar Baral, Prahallad Mishra, Pradyumna Kumar Mishra, Samir Kumar Patra
Cellular physiology is critically regulated by multiple signaling nexuses, among which cell death mechanisms play crucial roles in controlling the homeostatic landscape at the tissue level within an organism. Apoptosis, also known as programmed cell death, can be induced by external and internal stimuli directing the cells to commit suicide in unfavourable conditions. In contrast, stress conditions
-
Conquering chemoresistance in pancreatic cancer: Exploring novel drug therapies and delivery approaches amidst desmoplasia and hypoxia Cancer Lett. (IF 9.7) Pub Date : 2024-03-06 Pavan Kumar Chintamaneni, Sai Kiran S.S. Pindiprolu, Swati Swagatika Swain, Veera Venkata Satyanarayana Reddy Karri, Jerry Nesamony, Selvam Chelliah, Mahendran Bhaskaran
Pancreatic cancer poses a significant challenge within the field of oncology due to its aggressive behaviour, limited treatment choices, and unfavourable outlook. With a mere 10% survival rate at the 5-year mark, finding effective interventions becomes even more pressing. The intricate relationship between desmoplasia and hypoxia in the tumor microenvironment further complicates matters by promoting
-
Tumor-associated macrophages drive glycolysis through the IL-8/STAT3/GLUT3 signaling pathway in pancreatic cancer progression Cancer Lett. (IF 9.7) Pub Date : 2024-03-06 Ziyi Zhong, Kege Yang, Yunlong Li, Shurui Zhou, Hanming Yao, Yue Zhao, Yuzhou Huang, Jinmao Zou, Yaqing Li, Guoda Lian, Kaihong Huang, Shaojie Chen
Glycolytic metabolism is a hallmark of pancreatic ductal adenocarcinoma (PDAC), and tumor-associated stromal cells play important roles in tumor metabolism. We previously reported that tumor-associated macrophages (TAMs) facilitate PDAC progression. However, little is known about whether TAMs are involved in regulating glycolysis in PDAC. Here, we found a positive correlation between CD68 TAM infiltration
-
Hypoxia effects on glioblastoma progression through YAP/TAZ pathway regulation Cancer Lett. (IF 9.7) Pub Date : 2024-03-06 Carolina Castillo, Maddalena Grieco, Stefania D'Amone, Maria Grazia Lolli, Ornella Ursini, Barbara Cortese
The resistance of glioblastomas (GBM) to standard therapies poses a clinical challenge with limited survival despite interventions. The tumor microenvironment (TME) orchestrates GBM progression, comprising stromal and immune cells and is characterized by extensive hypoxic regions. Hypoxia activates the hypoxia-inducible factor 1 alpha (HIF-1α) pathway, interacting with the Hippo pathway (YAP/TAZ) in
-
TGF-β1/SMAD3-driven GLI2 isoform expression contributes to aggressive phenotypes of hepatocellular carcinoma Cancer Lett. (IF 9.7) Pub Date : 2024-03-05 Jia Ding, Yong-Yu Yang, Peng-Tao Li, Yue Ma, Li Zhang, Yuan Zhou, Cheng Jin, Hui-Yan Li, Yuan-Fei Zhu, Xiu-Ping Liu, Zheng-Jin Liu, Hu-Liang Jia, Ping-Guo Liu, Jian Wu
Hedgehog signaling is activated in response to liver injury, and modulates organogenesis. However, the role of non-canonical hedgehog activation via TGF-β1/SMAD3 in hepatic carcinogenesis is poorly understood. TGF-β1/SMAD3-mediated non-canonical activation was found in approximately half of GLI2-positive hepatocellular carcinoma (HCC), and two new GLI2 isoforms with transactivating activity were identified
-
Engineered lactococcus lactis intrapleural therapy promotes regression of malignant pleural effusion by enhancing antitumor immunity Cancer Lett. (IF 9.7) Pub Date : 2024-03-02 Yue Fan, Aoxing Chen, Junmeng Zhu, Rui Liu, Yi Mei, Lin Li, Xiaoxuan Sha, Xiaonan Wang, Wei Ren, Lifeng Wang, Baorui Liu
Intrapleural immunotherapies have emerged as a prominent field in treating malignant pleural effusion (MPE). Among these, bacteria-based intrapleural therapy has exerted an anti-MPE effect by immuno-stimulating or cytotoxic properties. We previously engineered a probiotic (FOLactis) expressing a fusion protein of Fms-like tyrosine kinase 3 and co-stimulator OX40 ligands. FOLactis activates tumor antigen-specific
-
The stromal microenvironment endows pancreatic neuroendocrine tumors with spatially specific invasive and metastatic phenotypes Cancer Lett. (IF 9.7) Pub Date : 2024-03-02 Zeng Ye, Qiang Li, Yuheng Hu, Haifeng Hu, Junfeng Xu, Muzi Guo, Wuhu Zhang, Xin Lou, Yan Wang, Heli Gao, Desheng Jing, Guixiong Fan, Yi Qin, Yue Zhang, Xuemin Chen, Jie Chen, Xiaowu Xu, Xianjun Yu, Mingyang Liu, Shunrong Ji
Cancer-associated fibroblasts (CAFs) play an important role in a variety of cancers. However, the role of tumor stroma in nonfunctional pancreatic neuroendocrine tumors (NF-PanNETs) is often neglected. Profiling the heterogeneity of CAFs can reveal the causes of malignant phenotypes in NF-PanNETs. Here, we found that patients with high stromal proportion had poor prognosis, especially for that with
-
Glutamine inhibition combined with CD47 blockade enhances radiotherapy-induced ferroptosis in head and neck squamous cell carcinoma Cancer Lett. (IF 9.7) Pub Date : 2024-03-01 An Song, Lei Wu, Bo-Xin Zhang, Qi-Chao Yang, Yuan-Tong Liu, Hao Li, Liang Mao, Dian Xiong, Hai-Jun Yu, Zhi-Jun Sun
Head and neck squamous cell carcinoma (HNSCC) is a formidable cancer type that poses significant treatment challenges, including radiotherapy (RT) resistance. The metabolic characteristics of tumors present substantial obstacles to cancer therapy, and the relationship between RT and tumor metabolism in HNSCC remains elusive. Ferroptosis is a type of iron-dependent regulated cell death, representing
-
Investigating autophagy and intricate cellular mechanisms in hepatocellular carcinoma: Emphasis on cell death mechanism crosstalk Cancer Lett. (IF 9.7) Pub Date : 2024-03-01 Gang Wang, Xiaodi Jiang, Pedram Torabian, Zhi Yang
Hepatocellular carcinoma (HCC) stands as a formidable global health challenge due to its prevalence, marked by high mortality and morbidity rates. This cancer type exhibits a multifaceted etiology, prominently linked to viral infections, non-alcoholic fatty liver disease, and genomic mutations. The inherent heterogeneity of HCC, coupled with its proclivity for developing drug resistance, presents formidable
-
K48-linked deubiquitination of VGLL4 by USP15 enhances the efficacy of tumor immunotherapy in triple-negative breast cancer Cancer Lett. (IF 9.7) Pub Date : 2024-02-29 Xuehui Wang, Xiaochong Deng, Jiashu Hu, Wenfang Zheng, Danrong Ye, Xiqian Zhou, Lin Fang
Immunotherapy based on PD-1/PD-L1 antagonists has been demonstrated to be efficacious in inducing tumor remission in patients with triple-negative breast cancer (TNBC). However, tumor immune evasion caused by the PD-1/PD-L1 pathway inhibits the immunotherapeutic effect of PD-1/PD-L1 inhibitors against TNBC. Therefore, identifying potential targets for blocking the PD-1/PD-L1 pathway is a compelling
-
Improved antitumor effects elicited by an oncolytic HSV-1 expressing a novel B7H3nb/CD3 BsAb Cancer Lett. (IF 9.7) Pub Date : 2024-02-29 Zongliang Zhang, Nian Yang, Huaqing Lu, Yongdong Chen, Long Xu, Zeng Wang, Qizhong Lu, Kunhong Zhong, Zhixiong Zhu, Guoqing Wang, Hexian Li, Meijun Zheng, Weiwei Zhang, Hui Yang, Xingchen Peng, Liangxue Zhou, Aiping Tong
Oncolytic viruses have emerged as a promising modality for cancer treatment due to their unique abilities to directly destroy tumor cells and modulate the tumor microenvironment. Bispecific T-cell engagers (BsAbs) have been developed to activate and redirect cytotoxic T lymphocytes, enhancing the antitumor response. To take advantage of the specific infection capacity and carrying ability of exogenous
-
Pharmacological approaches for targeting lysosomes to induce ferroptotic cell death in cancer Cancer Lett. (IF 9.7) Pub Date : 2024-02-29 Ji Feng, Zi-Xuan Wang, Jin-Lian Bin, Yong-Xin Chen, Jing Ma, Jing-Huan Deng, Xiao-Wei Huang, Jing Zhou, Guo-Dong Lu
Lysosomes are crucial organelles responsible for the degradation of cytosolic materials and bulky organelles, thereby facilitating nutrient recycling and cell survival. However, lysosome also acts as an executioner of cell death, including ferroptosis, a distinctive form of regulated cell death that hinges on iron-dependent phospholipid peroxidation. The initiation of ferroptosis necessitates three
-
Exosomal circRNAs: Novel biomarkers and therapeutic targets for urinary tumors Cancer Lett. (IF 9.7) Pub Date : 2024-02-28 Qiang Liu, Shenglong Li
Exosomal circRNAs have emerged as promising biomarkers and therapeutic targets for urinary tumors. In this review, we explored the intricate role of exosomal circRNAs in urological cancers, focusing on their biological functions, dysregulation in tumors, and potential clinical applications. The review delves into the mechanisms by which exosomal circRNAs contribute to tumor progression and highlights
-
TP53 in MDS and AML: Biological and clinical advances Cancer Lett. (IF 9.7) Pub Date : 2024-02-27 Yeqian Zhao, Weihao Chen, Jing Yu, Shanshan Pei, Qiang Zhang, Jimin Shi, He Huang, Yanmin Zhao
Recently, the WHO-5 and the ICC 2022 criteria have emphasized poor prognosis in AML/MDS patients with multi-hit mutations, whereas mutated plays a critical role in tumorigenesis, drawing substantial interest in exploring its biological behaviors. Diverse characteristics of mutations, including types, VAF, CNVs, allelic status, karyotypes, and concurrent mutations have been extensively studied. Novel
-
APIP regulated by YAP propels methionine cycle and metastasis in head and neck squamous cell carcinoma Cancer Lett. (IF 9.7) Pub Date : 2024-02-27 Jiayi Li, Ruijie Wang, Mingyu Li, Zhiyuan Zhang, Shufang Jin, Hailong Ma
The Yes-associated protein (YAP) plays a vital role in tumor progression and metabolic regulation. However, the involvement of YAP in metabolic reprogramming of head and neck squamous cell carcinoma remains unclear. Using RNA sequencing and ultra-high-performance liquid chromatography-tandem mass spectrometry, we observed that YAP increased the levels of the main metabolites and enzymes involved in
-
Seizing the fate of lymph nodes in immunotherapy: To preserve or not? Cancer Lett. (IF 9.7) Pub Date : 2024-02-27 Zhen-Yu Xu, Zi-Zhan Li, Lei-Ming Cao, Nian-Nian Zhong, Xuan-Hao Liu, Guang-Rui Wang, Yao Xiao, Bing Liu, Lin-Lin Bu
Lymph node dissection has been a long-standing diagnostic and therapeutic strategy for metastatic cancers. However, questions over myriad related complications and survival outcomes are continuously debated. Immunotherapy, particularly neoadjuvant immunotherapy, has revolutionized the conventional paradigm of cancer treatment, yet has benefited only a fraction of patients. Emerging evidence has unveiled
-
CircUBE3A(2,3,4,5) promotes adenylate-uridylate-rich binding factor 1 nuclear translocation to suppress prostate cancer metastasis Cancer Lett. (IF 9.7) Pub Date : 2024-02-27 Ziwei Wei, Cong Zhang, Yufeng Song, Dunsheng Han, Jinke Liu, Xiaoming Song, Fan Chao, Shiyu Wang, Guoxiong Xu, Gang Chen
Metastatic progression is the primary cause of mortality in prostate cancer (PCa) patients. Although circular RNAs (circRNAs) have been implicated in cancer progression and metastasis, our current understanding of their role in PCa metastasis remains limited. In this study, we identified that circUBE3A (2,3,4,5), which originated from exons 2, 3, 4 and 5 of the human ubiquitin-protein ligase E3A ()
-
Clinicopathological and molecular landscape of 5-year IDH-wild-type glioblastoma survivors: A multicentric retrospective study Cancer Lett. (IF 9.7) Pub Date : 2024-02-27 Evelina Miele, Elena Anghileri, Chiara Calatozzolo, Elisabetta Lazzarini, Sara Patrizi, Andrea Ciolfi, Lucia Pedace, Monica Patanè, Luana Abballe, Rosina Paterra, Luisa Maddaloni, Sabina Barresi, Angela Mastronuzzi, Alessandra Petruzzi, Irene Tramacere, Mariangela Farinotti, Lorena Gurrieri, Elena Pirola, Mauro Scarpelli, Giuseppe Lombardi, Veronica Villani, Matteo Simonelli, Rossella Merli, Andrea
Five-year glioblastoma (GBM) survivors (LTS) are the minority of the isocitrate dehydrogenase ()-wild-type GBM patients, and their molecular fingerprint is still largely unexplored. This multicenter retrospective study analyzed a large LTS-GBM cohort from nine Italian institutions and molecularly characterized a subgroup of patients by mutation, DNA methylation (DNAm) and copy number variation (CNV)
-
Circulating tumor cell clustering modulates RNA splicing and polyadenylation to facilitate metastasis Cancer Lett. (IF 9.7) Pub Date : 2024-02-27 Quanyou Wu, Zhaoru Gu, Bingqing Shang, Duo Wan, Qi Zhang, Xiaoli Zhang, Peipei Xie, Shujun Cheng, Wen Zhang, Kaitai Zhang
Circulating tumor cell (CTC) clusters exhibit significantly higher metastatic potential compared to single CTCs. However, the underlying mechanism behind this phenomenon remains unclear, and the role of posttranscriptional RNA regulation in CTC clusters has not been explored. Here, we conducted a comparative analysis of alternative splicing (AS) and alternative polyadenylation (APA) profiles between
-
Lovastatin/SN38 co-loaded liposomes amplified ICB therapeutic effect via remodeling the immunologically-cold colon tumor and synergized stimulation of cGAS-STING pathway Cancer Lett. (IF 9.7) Pub Date : 2024-02-25 Yi Yang, Jialong Qi, Jialin Hu, You Zhou, Jiena Zheng, Wenxia Deng, Muhammad Inam, Jiaxin Guo, Yongyi Xie, Yuan Li, Chuanshan Xu, Wei Deng, Wenjie Chen
Current immune checkpoint blockade (ICB) immunotherapeutics have revolutionized cancer treatment. However, many cancers especially the “immunologically cold” tumors, do not respond to ICB, prompting the search for additional strategies to achieve durable responses. The cGAS-STING pathway, as an essential immune response pathway, has been demonstrated for a potent target to sensitize ICB immunotherapy
-
Sialyltransferase ST3GAL4 confers osimertinib resistance and offers strategies to overcome resistance in non-small cell lung cancer Cancer Lett. (IF 9.7) Pub Date : 2024-02-24 Rui Han, Caiyu Lin, Conghua Lu, Yubo Wang, Jun Kang, Chen Hu, Yuanyao Dou, Di Wu, TingTing He, Huan Tang, Jie Zheng, Li Li, Yong He
The third-generation EGFR-TKI osimertinib is widely used in EGFR-mutated positive non-small cell lung cancer (NSCLC) patients, but drug resistance is inevitable. The currently known mechanisms only explain resistance in a small proportion of patients. For most patients, the mechanism of osimertinib resistance is still unclear, especially for EGFR-independent resistance. Herein, we thoroughly investigated
-
Clinical sequencing defines the somatic and germline mutation landscapes of Chinese HER2-Low Breast Cancer Cancer Lett. (IF 9.7) Pub Date : 2024-02-24 Bo-Yue Han, Chao Chen, Hong Luo, Cai-Jin Lin, Xiang-Chen Han, Javaria Nasir, Jin-Xiu Shi, Wei Huang, Zhi-Ming Shao, Hong Ling, Xin Hu
More than half of the breast cancer initially labeled as human epidermal growth factor receptor 2 (HER2)-negative actually exhibited low HER2 levels (IHC 1+ or IHC 2+/FISH-) and were classified as HER2-low breast cancer. Previous research emphasized the significant biological heterogeneity in HER2-low breast cancer, highlighting the importance of accurately characterizing HER2-low tumors to promote
-
Potential role of p53 deregulation in modulating immune responses in human malignancies: A paradigm to develop immunotherapy Cancer Lett. (IF 9.7) Pub Date : 2024-02-24 Shivi Chauhan, Shivani Jaiswal, Vibhuti Jakhmola, Bhavana Singh, Sujata Bhattacharya, Manoj Garg, Shinjinee Sengupta
The crucial role played by the oncogenic expression of , stemming from mutation or amyloid formation, in various human malignancies has been extensively studied over the past two decades. Interestingly, the potential role of as a crucial player in modulating immune responses has provided new insight into the field of cancer biology. The loss of p53's transcriptional functions and/or the acquisition
-
LINC02454-CCT complex interaction is essential for telomerase activity and cell proliferation in head and neck squamous cell carcinoma Cancer Lett. (IF 9.7) Pub Date : 2024-02-23 Biying Chen, Yue Weng, Mingyue Li, Zhouliang Bian, Ye Tao, Wenkai Zhou, Hong Lu, Shufang He, Rijing Liao, Jie Huang, Qian Wang, Ming Xu, Yunhui Ge, Wei Cao, Ming Lei, Yanjie Zhang
Telomerase activity is upregulated in head and neck squamous cell carcinoma (HNSCC), yet its regulatory mechanisms remain unclear. Here, we identified a cancer-specific lncRNA (LINC02454) associated with poor prognosis by using LncRNA chip of our HNSCC cohorts and external datasets. Through employing negative-stain transmission electron microscopy (NS-), we discovered an interaction between LINC02454
-
CD63+ cancer-associated fibroblasts confer CDK4/6 inhibitor resistance to breast cancer cells by exosomal miR-20 Cancer Lett. (IF 9.7) Pub Date : 2024-02-23 Jiahui Sun, Ruoxin Du, Xiaoju Li, Chenlin Liu, Donghui Wang, Xiangmei He, Guodong Li, Kuo Zhang, Shuning Wang, Qiang Hao, Yingqi Zhang, Meng Li, Yuan Gao, Cun Zhang
Cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors (CDK4/6i) have rapidly received Food and Drug Administration (FDA) approval as a new type of therapy for patients with advanced hormone receptor-positive breast cancer. However, with the widespread application of CDK4/6i, drug resistance has become a new challenge for clinical practice and has greatly limited the treatment effect. Here, the whole
-
Targeting O-GlcNAcylation in cancer therapeutic resistance: The sugar Saga continues Cancer Lett. (IF 9.7) Pub Date : 2024-02-23 Lulu Chen, Mengxue Hu, Luojun Chen, Yihan Peng, Cai Zhang, Xin Wang, Xiangpan Li, Yi Yao, Qibin Song, Jing Li, Huadong Pei
-linked-N-acetylglucosaminylation (-GlcNAcylation), a dynamic post-translational modification (PTM), holds profound implications in controlling various cellular processes such as cell signaling, metabolism, and epigenetic regulation that influence cancer progression and therapeutic resistance. From the therapeutic perspective, -GlcNAc modulates drug efflux, targeting and metabolism. By integrating
-
PD-1 regulation in immune homeostasis and immunotherapy Cancer Lett. (IF 9.7) Pub Date : 2024-02-23 Minling Gao, Jie Shi, Xiangling Xiao, Yingmeng Yao, Xu Chen, Bin Wang, Jinfang Zhang
Harnessing the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis is pivotal in autoimmunity and cancer immunotherapy. PD-1 receptors on immune cells engage with one of its ligands, PD-L1 or PD-L2, expressed on antigen-presenting cells or tumor cells, driving T-cell dysfunction and tumor immune escape. Thus, targeting PD-1/PD-L1 revitalizes cytotoxic T cells for cancer elimination
-
Fundamental insights and molecular interactions in pancreatic cancer: Pathways to therapeutic approaches Cancer Lett. (IF 9.7) Pub Date : 2024-02-23 Ming Gu, Yang Liu, Peng Xin, Wei Guo, Zimo Zhao, Xu Yang, Ruiyang Ma, Taiwei Jiao, Wenhui Zheng
The gastrointestinal tract can be affected by a number of diseases that pancreatic cancer (PC) is a malignant manifestation of them. The prognosis of PC patients is unfavorable and because of their diagnosis at advanced stage, the treatment of this tumor is problematic. Owing to low survival rate, there is much interest towards understanding the molecular profile of PC in an attempt in developing more
-
-
Unleashing the power of immune checkpoints: Post-translational modification of novel molecules and clinical applications Cancer Lett. (IF 9.7) Pub Date : 2024-02-22 Jie Wang, Yian Wang, Xianjie Jiang, Meifang Xu, Meifeng Wang, Rong Wang, Boshu Zheng, Mingfen Chen, Qi Ke, Jun Long
Immune checkpoint molecules play a pivotal role in the initiation, regulation, and termination of immune responses. Tumor cells exploit these checkpoints to dampen immune cell function, facilitating immune evasion. Clinical interventions target this mechanism by obstructing the binding of immune checkpoints to their ligands, thereby restoring the anti-tumor capabilities of immune cells. Notably, therapies
-
Antigen/HLA-agnostic strategies for Characterizing Tumor-responsive T cell receptors in PDAC patients via single-cell sequencing and autologous organoid application Cancer Lett. (IF 9.7) Pub Date : 2024-02-22 Xu Wang, Zhengjie Dai, Xuan Lin, Xuan Zou, Ruijie Wang, Yesboli Tasiheng, Yu Yan, Mingjian Ma, Yusheng Chen, He Cheng, Chen Liu, Xianjun Yu
-
Revitalizing antitumor immunity: Leveraging nucleic acid sensors as therapeutic targets Cancer Lett. (IF 9.7) Pub Date : 2024-02-22 Dan-Feng Liu, Wei He, Lei-Lei Yang
-
Identification of a 9-gene signature to enhance biochemical recurrence prediction in primary prostate cancer: A benchmarking study using ten machine learning methods and twelve patient cohorts Cancer Lett. (IF 9.7) Pub Date : 2024-02-22 Wenjun Yin, Guo Chen, Yutong Li, Ruidong Li, Zhenyu Jia, Chuanfan Zhong, Shuo Wang, Xiangming Mao, Zhouda Cai, Junhong Deng, Weide Zhong, Bin Pan, Jianming Lu
Prostate cancer (PCa) is a prevalent malignancy among men worldwide, and biochemical recurrence (BCR) after radical prostatectomy (RP) is a critical turning point commonly used to guide the development of treatment strategies for primary PCa. However, the clinical parameters currently in use are inadequate for precise risk stratification and informing treatment choice. To address this issue, we conducted
-
Lnc-PLCB1 is stabilized by METTL14 induced m6A modification and inhibits Helicobacter pylori mediated gastric cancer by destabilizing DDX21 Cancer Lett. (IF 9.7) Pub Date : 2024-02-21 Mingjie Chang, Qiyu Sun, Xixi Cui, Yuqiong Wang, Jiayi Liu, Zenghui Sun, Juchao Ren, Yundong Sun, Lihui Han, Wenjuan Li
-
A growth factor-reduced culture system for colorectal cancer organoids Cancer Lett. (IF 9.7) Pub Date : 2024-02-19 Ronghui Tan, Ze Zhang, Peirong Ding, Yue Liu, Huidong Liu, Minyi Lu, Ye-Guang Chen
Although organoids derived from tumor tissues have been widely used in cancer research, it is a great challenge for cultured organoids to retain the characteristics of the original tumor tissues due to their heterogeneity. In this study, we explore organoid culture recipes to capture tumor features of colorectal cancers. We find that the activation of Wnt and EGF signaling and inhibition of BMP signaling
-
From lymphopenia to restoration: IL-7 immunotherapy for lymphocyte recovery in glioblastoma Cancer Lett. (IF 9.7) Pub Date : 2024-02-17 Joonseok Kim, Haeyoun Choi, Sin-Soo Jeun, Stephen Ahn
Glioblastoma, the most prevalent malignant primary brain tumor, presents substantial treatment challenges because of its inherent aggressiveness and limited therapeutic options. Lymphopenia, defined as reduced peripheral blood lymphocyte count, commonly occurs as a consequence of the disease and its treatment. Recent studies have associated lymphopenia with a poor prognosis. Factors that contribute
-
MST1/2: Important regulators of Hippo pathway in immune system associated diseases Cancer Lett. (IF 9.7) Pub Date : 2024-02-17 Jingjing Zhou, Lanfang Li, Baojin Wu, Zhen Feng, Ying Lu, Zuoyun Wang
The Hippo signaling pathway is first found in and is highly conserved in evolution. Previous studies on this pathway in mammals have revealed its key role in cell proliferation and differentiation, organ size control, and carcinogenesis. Apart from these, recent findings indicate that mammalian Ste20-like kinases 1 and 2 (MST1/2) have significant effects on immune regulation. In this review, we summarize
-
STING inhibitors sensitize platinum chemotherapy in ovarian cancer by inhibiting the CGAS-STING pathway in cancer-associated fibroblasts (CAFs) Cancer Lett. (IF 9.7) Pub Date : 2024-02-17 Jiale Liu, Chenmian Liu, Yana Ma, Xiyu Pan, Ran Chu, Shu Yao, Junyu Chen, Chang Liu, Zhongshao Chen, Chenchen Sheng, Kai Zhang, Ying Xue, Helgi B. Schiöth, Beihua Kong, Qing Zhang, Kun Song
Chemotherapy resistance in ovarian cancer hampers cure rates, with cancer-associated fibroblasts (CAFs) playing a pivotal role. Despite their known impact on cancer progression and chemotherapy resistance, the specific mechanism by which CAFs regulate the tumor inflammatory environment remains unclear. This study reveals that cisplatin facilitates DNA transfer from ovarian cancer cells to CAFs, activating
-
JunD-miR494-CUL3 axis promotes radioresistance and metastasis by facilitating EMT and restraining PD-L1 degradation in esophageal squamous cell carcinoma Cancer Lett. (IF 9.7) Pub Date : 2024-02-17 Xin Li, Ji Cong, Xuantong Zhou, Wenyan Gao, Wenxin Li, Qi Yang, Xinyue Li, Zhihua Liu, Aiping Luo
Therapy resistance and metastatic progression jointly determine the fatal outcome of cancer, therefore, elucidating their crosstalk may provide new opportunities to improve therapeutic efficacy and prevent recurrence and metastasis in esophageal squamous cell carcinoma (ESCC). Here, we have established radioresistant ESCC cells with the remarkable metastatic capacity, and identified miR-494-3p (miR494)
-
m6A/HOXA10-AS/ITGA6 axis aggravates oxidative resistance and malignant progression of laryngeal squamous cell carcinoma through regulating Notch and Keap1/Nrf2 pathways Cancer Lett. (IF 9.7) Pub Date : 2024-02-17 Kai Zhao, Liwei Chen, Yingli Xie, Nan Ren, Jianhui Li, Xingyou Zhai, Shikang Zheng, Kun Liu, Cheng Wang, Qibing Qiu, Xin Peng, Wenjia Wang, Jinjing Liu, Qin Che, Junda Fan, Hai Hu, Mingbo Liu
As the second most prevalent malignant tumor of head and neck, laryngeal squamous cell carcinoma (LSCC) imposes a substantial health burden on patients worldwide. Within recent years, resistance to oxidative stress and N6-methyladenosine (m6A) of RNA have been proved to be significantly involved in tumorigenesis. In current study, we investigated the oncogenic role of m6A modified long non coding RNAs
-
CD24 negativity reprograms mitochondrial metabolism to PPARα and NF-κB-driven fatty acid β-oxidation in triple-negative breast cancer Cancer Lett. (IF 9.7) Pub Date : 2024-02-17 Divya Murthy, Debasmita Dutta, Kuldeep S. Attri, Tagari Samanta, Sukjin Yang, Kwang Hwa Jung, Sarah G. Latario, Vasanta Putluri, Shixia Huang, Nagireddy Putluri, Jun Hyoung Park, Benny Abraham Kaipparettu
CD24 is a well-characterized breast cancer (BC) stem cell (BCSC) marker. Primary breast tumor cells having CD24-negativity together with CD44-positivity is known to maintain high metastatic potential. However, the functional role of CD24 gene in triple-negative BC (TNBC), an aggressive subtype of BC, is not well understood. While the significance of CD24 in regulating immune pathways is well recognized
-
Biological functions and clinical significance of tRNA-derived small fragment (tsRNA) in tumors: Current state and future perspectives Cancer Lett. (IF 9.7) Pub Date : 2024-02-16 Qun Chen, Danrui Li, Luyang Jiang, Yang Wu, Hao Yuan, Guodong Shi, Fengyuan Liu, Pengfei Wu, Kuirong Jiang
A new class of noncoding RNAs, tsRNAs are not only abundant in humans but also have high tissue specificity. Recently, an increasing number of studies have explored the correlations between tsRNAs and tumors, showing that tsRNAs can affect biological behaviors of tumor cells, such as proliferation, apoptosis and metastasis, by modulating protein translation, RNA transcription or posttranscriptional
-
Nanodiamonds: Next generation nano-theranostics for cancer therapy Cancer Lett. (IF 9.7) Pub Date : 2024-02-16 Nivedita Priyadarshni, Rajesh Singh, Manoj K. Mishra
Cancer remains a leading global cause of mortality, demanding early diagnosis and effective treatment. Traditional therapeutic methods often fall short due to their need for more specificity and systemic toxicity. In this challenging landscape, nanodiamonds (ND) emerge as a potential solution, mitigating the limitations of conventional approaches. ND are tiny carbon particles that mimic traditional
-
Schwann cells in pancreatic cancer: Unraveling their multifaceted roles in tumorigenesis and neural interactions Cancer Lett. (IF 9.7) Pub Date : 2024-02-15 Zhiwei Cai, Hongfei Yao, Jiahao Chen, Abousalam Abdoulkader Ahmed, Chunjing Li, Xiao Hu, Xiaoyan Tang, Chongyi Jiang
Pancreatic ductal adenocarcinoma (PDAC), characterized by heightened neural density, presents a challenging prognosis primarily due to perineural invasion. Recognized for their crucial roles in neural support and myelination, Schwann cells (SCs) significantly influence the process of tumorigenesis. This review succinctly outlines the interplay between PDAC and neural systems, positioning SCs as a nexus
-
CRISPR genome-wide screening identifies PAK1 as a critical driver of ARSI cross-resistance in prostate cancer progression Cancer Lett. (IF 9.7) Pub Date : 2024-02-15 Haojie Chen, Keqin Dong, Jie Ding, Jia Xia, Fajun Qu, Fuying Lan, Haihong Liao, Yuhang Qian, Jiacheng Huang, Zihan Xu, Zhengqin Gu, Bowen Shi, Mingming Yu, Xingang Cui, Yongjiang Yu